Pharmacotherapeutic group: antiviral agent
ATX code: J05AX13
Antiviral agent. Specifically suppresses in vitro influenza viruses A and B (Influenzavirus A, B), including highly pathogenic subtypes A(H1N1)pdm09 and A(H5N1), and other viruses – causative agents of acute respiratory viral infections (ARI), associated with severe acute respiratory syndrome (SARS), rhinovirus (Rhinovirus), adenovirus (Adenovirus), respiratory syncytial virus (Pneumovirus), and parainfluenza virus (Paramyxovirus).
In terms of the mechanism of antiviral action it refers to fusion inhibitors (fusion), interacts with hemagglutinin of the virus and prevents fusion of the lipid shell of the virus and cell membranes.
It has a moderate immunomodulatory effect, increases the body’s resistance to viral infections. It possesses interferon-inducing activity – in researches on mice interferon induction was noticed after 16 hours, and high titers of interferon were maintained in blood up to 48 hours after administration.
Stimulates cellular and humoral immune reactions: it increases number of lymphocytes in blood, in particular of T-cells (CD3), increases number of T-helpers (CD4) without affecting the level of T-suppressors ‑(CD8), normalizes the immunoregulatory index, stimulates phagocytic function of macrophages and increases the number of natural killer (NK-cells).
Therapeutic effectiveness in viral infections is manifested in reduction of duration and severity of the course of the disease and its main symptoms as well as in the decrease of the rate of development of complications due to viral infection and exacerbations of chronic bacterial diseases.
In treatment of influenza or acute respiratory viral infections in adults the clinical trial showed that the effect of Arbidol® in adults is most pronounced in acute period of disease and shows shorter time of resolution of disease symptoms, less severe manifestations of disease and shorter time of virus elimination.
Therapy with Arbidol® results in higher rate of resolution of symptoms on the third day of therapy compared to placebo. In 60 hours after the beginning of therapy the resolution of all symptoms of laboratory confirmed flu is more than 5 times higher than in the placebo group.
A significant effect of Arbidol® on the rate of elimination of the influenza virus was found, which was manifested, in particular, by a decrease in the frequency of detection of RNA of the virus on the 4th day.
Related to low-toxicity drugs (LD50 > 4 g/kg). It does not have any negative effect on human body when administered orally in recommended doses.
It is rapidly absorbed and distributed to organs and tissues. Maximal concentration in blood plasma is reached after 1.5 hours. It is metabolized in the liver. Period of half-life is 17-21 hours. About 40% is eliminated unchanged, mainly in bile (38.9%) and in small amount in kidney (0.12%). During the first day 90% of the administered dose is eliminated.
Prevention of flu and colds, Colds, ARI, Flu
Prevention and treatment in adults and children: influenza A and B, other ARI.
The complex therapy of recurrent herpetic infection.
Prevention of postoperative infectious complications.
- Comprehensive therapy of acute intestinal infections of rotavirus aetiology in children over 6 years
Active ingredient: umiphenovir hydrochloride monohydrate (in terms of umiphenovir hydrochloride) – 100 mg.
Excipients: potato starch – 30.14 mg, microcrystalline cellulose – 55.76 mg, colloidal silica (aerosil) – 2.0 mg, povidone K 25 (collidon 25) – 10.1 mg, calcium stearate – 2.0 mg.
Solid gelatin capsules № 1:
Case: titanium dioxide (E 171) – 2.0000%, gelatin – up to 100%.
Lid: titanium dioxide (E 171) – 1.3333 %, sunset yellow dye (E 110) – 0.0044 %, quinoline yellow (E 104) – 0.9197 %, gelatin – up to 100%.
How to take, the dosage
Ingestion, before meals.
The single dose of the drug (depending on age):
|Children 6 to 12 years old||100 mg (1 capsule )|
|Children over 12 years of age and adults||200 mg (2 capsules)|
Dosing regimen (depending on age):
|In children from 6 years and adults:|
|Non-specific prophylaxis during epidemics of influenza and other acute respiratory infections||in a single dose 2 times a week for 3 weeks|
|Non-specific prophylaxis in direct contact with patients with influenza and other acute respiratory viral infections||in a single dose once a day for 10-14 days|
|Treatment of influenza and other acute respiratory infections||in a single dose 4 times a day (every 6 hours) for 5 days|
|In a single dose/td>|
|Complex therapy of recurrent herpetic infection|| in a single dose 4 times a day (every 6 hours)|
for 5-7 days, then a single dose 2 times a week for 4 weeks
|Hypotherapy of recurrent herpes infections/td>|
|Prevention of postoperative infectious complications||In a single dose 2 days before surgery, then on the 2nd and 5th day after surgery|
|In children from 6 years old:|
|Complex therapy of acute intestinal infections of rotavirus etiology||in a single dose 4 times a day (every 6 hours) for 5 days|
Please only use the drug according to the indication, route of administration, and dosage listed in the instructions.
The drug should be taken as soon as the first symptoms of influenza or other colds appear, preferably within 3 days after the beginning of the illness.
If after three days of using Arbidol® during treatment of influenza and other acute respiratory viral infections the severity of symptoms, including high temperature (38 °С or higher) persists, it is necessary to see a doctor to evaluate the appropriateness of the drug.
In the treatment of influenza and acute respiratory infections, concomitant symptomatic therapy is possible, including antipyretic drugs, mucolytic and local vasoconstrictors.
No adverse effects have been observed when prescribed with other drugs.
Special clinical studies to study the interactions of the drug Arbidol ® with other medicinal products have not been conducted.
In the conditions of clinical trials no adverse interactions with antipyretics, mucolytic and local vasoconstrictors have been revealed.
It is necessary to follow the recommended regimen and duration of drug administration. If one dose of the drug is missed, the missed dose should be taken as soon as possible and the course of the drug should be continued according to the original schedule.
If after three days of using the drug Arbidol® in treatment of influenza and other acute respiratory infections the severity of symptoms, including high fever (38 °С or more) persists, it is necessary to see a doctor to evaluate the appropriateness of the drug.
Impact on the ability to drive vehicles and mechanisms:
It does not exhibit central neurotropic activity and can be used in medical practice in persons of various professions, including those requiring increased attention and coordination of movements (drivers of transport, operators, etc.).
Hypersensitivity to ubifenovir or any component of the drug; children under 6 years of age. First trimester of pregnancy. Breast-feeding period.
The second and third trimesters of pregnancy.
The drug Arbidol® is a low-toxicity drug and is usually well tolerated.
The side effects are rare, usually mild to moderate and transient.
The incidence of adverse drug reactions is defined according to the WHO classification: very common (more than 1/10), common (at least 1/100 but less than 1/10), infrequent (at least 1/1000 but less than 1/100), rare (at least 1/10000 but less than 1/1000), very rare (less than 1/10000), frequency unknown (cannot be known from available data).
Immune system disorders: rare – allergic reactions.
If any of the side effects listed in the instructions worsen, or if you notice any other side effects not listed in the instructions, tell your doctor.
Harmful effects on pregnancy, embryo and fetal development, labor and postnatal development have not been found in animal studies. The use of the drug Arbidol® in the first trimester of pregnancy is contraindicated.
In the second and third trimesters of pregnancy Arbidol® may be used only for the treatment and prevention of influenza and if the estimated benefit to the mother exceeds the potential risk to the fetus. The benefit/risk ratio is determined by the treating physician.
It is unknown whether Arbidol® penetrates into the breast milk in women during lactation. If it is necessary to use Arbidol®, breastfeeding should be stopped.
Arbidol Maximum, Arpeflu, Afludol, Umifenovir
3 years. Do not use after the expiration date stated on the package
|Conditions of storage|
Store at a temperature not exceeding 25 oC. Keep out of reach of children.
Buy Arbidol, capsules 100 mg 20 pcs with delivery to USA, UK, Europe and over 120 other countries.